



MYOS RENS TECHNOLOGY TO EXHIBIT MYOS CANINE MUSCLE FORMULA™ AT THE ATLANTIC COAST VETERINARY CONFERENCE, OCTOBER 8-11, 2018

CEDAR KNOLLS, N.J., September 26, 2018 -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that MYOS will exhibit at the **Atlantic Coast Veterinary Conference** in Atlantic City, NJ, from **October 8-11, 2018**. Featured at the event will be **MYOS Canine Muscle Formula™** our first Fortetropin®-based veterinary product.

For 29 years, the Atlantic Coast Veterinary Conference (ACVC) has been providing veterinary healthcare professionals with unmatched continuing education and networking opportunities. This year, ACVC will be proudly presented by *American Veterinarian*® – the premier news and information resource for the veterinary profession. Please visit **Booth #624** to learn about Fortetropin's benefits for aging dogs who are experiencing muscle loss, or go to www.myospet.com.

Fortetropin® has been clinically shown to increase lean muscle size and mass in humans *and* addresses muscle loss and supports muscle health in dogs. Fortetropin is a unique bioactive composition derived from fertilized egg yolk and is manufactured using a patented technology in order to retain its nutrient-dense nature and biological integrity and bioactivity. Attendees will also be able to purchase **MYOS Canine Muscle Formula** at specially discounted conference prices.

Joseph Mannello, Chief Executive Officer of MYOS, commented, "The [ACVC](#) is attended by over 2,000 people in the veterinary and animal health fields. *American Veterinarian*, the show's sponsor, expresses that its 'mission is to provide a broader view of medicine that encompasses the intertwined worlds of science, medicine, and health'. We look forward to the opportunity to connect with veterinary professionals at this conference, educating and providing greater awareness of the benefits of Fortetropin in our MYOS Canine Muscle Formula."

About MYOS RENS Technology Inc.

MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic

initiatives, the successful launch of our products, including our Qurr[®], Yolked[®], and MYOS Canine Muscle Formula[™] products, the success of our research and development, the results of the clinical evaluation of Fortetropin[®] and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:

Porter LeVay & Rose

Michael Porter, President

Phone: 212-564-4700

Email: MYOS@plrinvest.com

###